Tackling ALK-positive LBCL

In this issue of Blood, Soumerai et al present the first patient-derived xenograft (PDX) mouse models of anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) to investigate novel therapeutic approaches for this rare aggressive lymphoma subtype.(1) The authors show that the next-generation ALK inhibitors alectinib and lorlatinib have promising activity in these preclinical in vivo PDX models and in intensively pre-treated patients with relapsed/refractory ALK-LBCL.

Automated summary

This study presents the first patient-derived xenograft (PDX) mouse models of anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL), aiming to investigate new therapeutic approaches. The researchers found that the next-generation ALK inhibitors, alectinib and lorlatinib, showed promising activity in both preclinical in vivo PDX models and heavily pre-treated patients with relapsed/refractory ALK-LBCL.